MedTrace Logo

Predicting Treatment Failure in HSIL Patients with Positive Margins After Conization Via Detection of PAX1 Methylation

NCT06713655 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2024-12-06

No results posted yet for this study

Summary

The goal of this multicenter, observational study is to evaluate whether methylation testing of paired box gene 1 (PAX1) can better predict and diagnose recurrence or persistent disease in patients with positive margins after cervical conization for high-grade squamous intraepithelial lesion (HSIL). The main question it aims to answer is:

Can PAX1 gene methylation testing provide a more accurate and effective prediction and diagnosis of cervical disease recurrence/persistence in addition to existing methods? Participants will be managed according to the latest clinical guidelines, and during follow-up, a non-invasive test, PAX1 gene methylation testing, will be added.

Conditions

  • High-grade Squamous Intraepithelial Lesions (HSIL)
  • Cervical Conization

Sponsors & Collaborators

  • Huzhou Maternity and Child Care Hospital

    collaborator UNKNOWN

  • Jiaxing Maternity and Child Health Care Hospital

    collaborator OTHER

  • Shaoxing Maternity and Child Health Care Hospital

    collaborator OTHER

  • Ningbo No. 1 Hospital

    collaborator OTHER

  • Jinhua Central Hospital

    collaborator OTHER

  • Taizhou Hospital Zhejiang Province

    collaborator UNKNOWN

  • Women's Hospital School Of Medicine Zhejiang University

    lead OTHER

Eligibility

Min Age
26 Years
Max Age
54 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2028-04-30
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06713655 on ClinicalTrials.gov